Wednesday 14 October 2026

One To Watch

PDC*Line Pharma

A clinical-stage biotech developing a new class of potent and scalable active immunotherapies for cancer.

Company Overview

Want to Update your Company's Profile?


Latest PDC*Line Pharma News

PDC*line Pharma and partners receive financing from Walloon region
17 January 2024
PDC*line Pharma welcomes Channa Debruyne as medical director
9 September 2019
PDC*line Pharma inks collaboration with LG Chem
20 March 2019
More PDC*Line Pharma news >


Today's issue

MHRA approves Onswik for diabetes
Pharmaceutical
MHRA approves Onswik for diabetes
13 October 2026
Pharmaceutical
Nimbus hires Merck & Co dealmaker as chief business officer
13 October 2026
Biotechnology
Rona Thera inks global license deal with Roche
13 October 2026
Pharmaceutical
J&J lifts 2026 guidance as Tremfya surge offsets Stelara decline
13 October 2026
Biotechnology
Positive Phase IIb results for Tortugas' obuprazine in schizophrenia
13 October 2026
Biotechnology
Sibylla names ex-Novartis cell and gene therapy head Usman Azam CEO
13 October 2026
Biosimilars
Formycon and Zydus’s Keytruda biosimilar BLA accepted by FDA
13 October 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze